Cambridge Healthtech Institute’s 6th Annual
Agonist Immunotherapy Targets
Priming the Immune System with Costimulatory Agents
May 7-8, 2020
The immunotherapies industry is currently dominated by antagonist antibodies such as PD-1 and CTLA-4, however, agonist targets play an equally critical role in improving the immune response across various types of cancer.
CHI’s Agonist Immunotherapy Targets conference brings together leading industry scientists and academics to examine the most promising agonist targets in development, supported by cutting-edge data and lessons learnt. Key targets include 4-1BB, OX40, CD137, CD40 and GITR, as well as developments in TNFR receptors, ICOS, STING, and VISTA – as monotherapies and in combination.
Preliminary Agenda
LATEST DEVELOPMENT IN ICOS, CD137
ICOS Agonism - The Next Generation of Immune Checkpoint Modulation for Cancer
Axel Hoos, PhD, Senior Vice President, Therapeutic Area Head, Oncology, GSK
Reverse Translational Approaches in Development of ICOS Agonist Vopratelimab
Elizabeth Trehu, MD, CMO, Jounce Therapeutics
Talk Title to be Announced
Bruce Keyt, PhD, CSO, IGM Biosciences
CD137 Bispecific Antibody Targeting the Tumor Microenvironment
Patrick Mayes, PhD, Executive Director, Head, IO Antibody Research, Incyte
OX40
Novel MOA of a PD1-OX40 Bispecific
Fiona Harding, PhD, Senior Research Fellow, Oncology Discovery, AbbVie
Elucidating How Nonlinked CD4+ Help Augments OX40 plus 4-1BB Agonist Immunotherapy
Adam J. Adler, Professor, Department of Immunology, UConn Health School of Medicine
Developing Novel Combinations to Enhance the Therapeutic Efficacy of OX40 Agonists
William L. Redmond, PhD, Associate Member and Director, Immune Monitoring Laboratory, Earle A. Chiles Research Institute, Providence Cancer Institute
CD40
CD40 and Anti-CD40 mAb Programs
Michael Yellin, MD, Vice President, Clinical Science, Celldex
Targeting CD40 to Unleash Dendritic Cells in Immuno-Oncology – Expanding the Tumor-Specific T Cell Repertoire
Peter Ellmark, PhD, Vice President, Discovery, Alligator Bioscience
Overcoming the Resistance to Agonist Immunotherapy
Bin Zhang MD, PhD, Professor, Department of Medicine –Division of Hematology/Oncology, Department of Microbiology-Immunology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity
Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs, Inc.
TNF
IL-15-Based Trifunctional Antibody Fusion Proteins with Costimulatory TNF-Superfamily Ligands for Cancer Immunotherapy
Dafne Müller, PhD, Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
TNFR2: Turning off for Cancer, Turning on for Autoimmunity
Denise L. Faustman, MD, PhD, Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
HERA-GITRL: A Unique Hexavalent GITR Agonist for Cancer Immunotherapy
Oliver Hill, PhD, Vice President, Molecular Biology, Apogenix
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
2020 PROGRAMS
View By:









Emerging Indications for Therapeutic Antibodies
Immunogenicity Case Studies and Clinical Management
Improving Immunotherapy Efficacy and Safety
Engineering Antibody-Drug Conjugates
Gene Therapy: Advancing from Bench to Clinic
Immunogenicity Assessment and Regulatory Approval of Biologics
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Optimizing Bioassays for Biologics
Clinical Progress of Antibody-Drug Conjugates
Characterization for Novel Biotherapeutics
Cell and Gene Therapy Analytics
Engineering Bispecific Antibodies
Protein Expression System Engineering